5 Opportunities To Accelerate The Drug Development Process

The pharmaceutical industry is consistently on a quest to expedite the process of bringing novel,
lifesaving drugs to the market. The conventional drug development cycle, which often spans
over a decade and costs billions, has numerous stages: drug discovery, preclinical testing, clinical
trials, FDA review, and finally, FDA approval.

Every stage is crucial but also fraught with time- and cost-related challenges, creating
bottlenecks that impede the rapid progress of drug discovery and development. Part of this
challenge is the mandate of some governments to transparently release the results of clinical
studies of drugs and medical devices within 120 days of the completion of the review.

Fortunately, some of these delimiting factors can be addressed. Here are five key opportunities
that could accelerate drug development, highlighting where the bottlenecks occur and how
cutting-edge technologies like artificial intelligence (AI), software solutions, and more can play a
transformative role.

AI In Data Collection, Analysis, And Real-World Evidence

Bottleneck: Manual data analysis and interpreting annotated CRFs is time-consuming and can
slow down the drug approval process. The tedious task of analyzing these manually can also lead
to data inaccuracies. Furthermore, traditional clinical trials often need more participant diversity,
making assessing how the drug will perform in different populations difficult.

Solution: AI and machine learning tools can significantly transform this process. They can
automate annotated CRFs analysis (aCRF) analysis, rapidly processing the captured data and
spotting trends and potential issues faster than human analysts. AI-driven platforms can ensure
data consistency, reduce errors, and expedite decision-making, making CRFs a much more
effective tool.

Electronic case report forms (eCRFs) are digital versions of CRFs and acts used in electronic
data capture (EDC) systems. An eCRF offers a more streamlined, efficient method for capturing
and managing clinical trial data. It reduces manual errors, increases data accuracy, and allows
real-time access to data, thus speeding up the entire data collection, analysis, and submission
process.

When trained to understand complex medical terminologies and recognize patterns in aCRFs,
machine learning models can make data extraction and interpretation faster and more reliable.
This approach could dramatically reduce the time between clinical trials and drug approval,
accelerating drug development.

Additionally, AI can assist in leveraging real-world evidence (RWE)—healthcare information
from everyday real-life settings. RWE, when combined with the high-quality data obtained from

aCRFs or eCRF and clinical trials, offers a more holistic understanding of a drug’s performance
across diverse patient populations. This combination can lead to more informed decisions about
the drug’s safety and efficacy, further accelerating the drug development timeline.

AI-Driven Drug Discovery

Bottleneck: The initial stage of drug discovery involves identifying biological targets and
suitable compounds. This process is labour-intensive, time-consuming, and subject to human
error.

Solution: Artificial intelligence (AI) can streamline this process and significantly reduce the
time spent on discovery. Machine learning algorithms are equipped to process vast amounts of
data in a fraction of the time it would take a human team rapidly identify potential therapeutic
compounds and predict their effectiveness and toxicity. For instance, a tool that predicts protein
structures with unprecedented accuracy has already proven the revolutionary impact of AI in
drug discovery.

Advanced Preclinical Testing Methods

Bottleneck: In traditional preclinical testing, the compound’s safety and effectiveness are tested
in animals. This stage is often time-consuming and expensive due to the high failure rate of
drugs, ethical concerns, and the variable predictability of animal models for human outcomes.

Solution: Innovative lab technologies like organs-on-a-chip and human-based micro-
physiological systems (MPS) can make preclinical testing more efficient and predictive. These
models simulate human biology better than animal models, which could lead to higher success
rates during the clinical trial phases. Additionally, machine learning algorithms can help identify
suitable candidates for preclinical trials, potentially reducing the failure rate.

Decentralized And Adaptive Clinical Trials

Bottleneck: Traditional clinical trial designs often require many patients, take years, and cost
millions. Furthermore, site-based trials can limit patient accessibility and participation.

Solution: Decentralized (virtual) and adaptive clinical trial designs can speed up drug
development. Decentralized trials use digital health technologies to enable patient participation
regardless of geographical location, thus increasing the recruitment rate and reducing trial times.
Similarly, adaptive trials allow for modifications to the trial design based on interim data,
reducing the risk of late-stage trial failure.

Furthermore, data can now be presented using sharp interactive displays and integrated
touchscreen platforms with embedded software so users can engage digital content in a dynamic, collaborative manner—allowing real-time writing, drawing, annotations, and modifications of
images and videos.

Streamlined Regulatory Approval Process

Bottleneck: The final stages of drug development involve a detailed review by regulatory bodies
like the FDA. This phase includes evaluating all the data from the discovery phase through
clinical trials, which can take several months to years due to the complexity and volume of
information to be reviewed.

Solution: Innovative software solutions and AI technologies can expedite this process by
simplifying data submission, streamlining data management, and enabling real-time, transparent
interactions with regulatory bodies.

For instance, platforms like Regulatory Information Management (RIM) offer a unified approach
to managing regulatory information. The software provides a centralized hub for all data related
to the drug development process, reducing complexity, enhancing transparency, and enabling
more efficient communication with regulatory authorities.

AI can be an important factor in the regulatory approval process by automating the preparation
of regulatory documents. This ensures completeness and consistency while identifying potential
issues that could lead to delays. AI tools can predict potential regulatory obstacles based on past
data, enabling proactive problem-solving and expedited approval.

Summary

The pharmaceutical industry can dramatically speed up the regulatory approval process through
the synergistic application of these advanced technologies, ultimately leading to faster market
access for lifesaving drugs.

Other articles from totimes.ca – otttimes.ca – mtltimes.ca